Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Megan Mcnerney

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentPathology
AddressChicago IL 60637
Phone+1 (773) 834-8896
Email
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    The McNerney lab studies the genomic changes in blood cancers with the goal of identifying therapeutic vulnerabilities. We focus on myeloid malignancies which are particularly difficult to treat. We apply a variety of functional genomics approaches and model systems to decipher changes in the cancer genome. Ongoing and available projects include studies of hematopoietic stem cell regulation, gene regulation during hematopoiesis, contiguous gene syndromes in cancer, and oncogenic signaling. Please visit our webpage for more information https://voices.uchicago.edu/mcnerneylab/


    Collapse Biography 
    Collapse education and training
    Northwestern University, EvanstonB.A.1999Molecular and Cellular Biology
    The University of Chicago, ChicagoPhD2005Immunology
    The University of Chicago , ChicagoMD2007Medicine
    The University of Chicago, ChicagoResidency2010Clinical Pathology
    The University of Chicago, ChicagoPostdoctoral2014Genomics and Systems Biology
    Collapse awards and honors
    1997Edgar Macey Scholarship for Summer Research, Northwestern University
    1999Graduation with Departmental Honors, Biological Sciences, Northwestern University
    1999Graduation Cum Laude, Northwestern University
    2000 - 2007Medical Scientist Training Program, NIH
    2003Elaine Frank Family Fellowship for Medical Research, MSTP, University of Chicago
    2004Doolittle-Harrison Travel Fellowship, University of Chicago
    2005Robert E. Priest Pathology Merit Award, Department of Pathology, University of Chicago
    2006Honorable Mention Best PhD Dissertation Award, Biological Sciences, University of Chicago
    2006Committee on Immunology Best PhD Thesis Award, University of Chicago
    2007Leon Jacobson Prize for Senior Scientific Presentation, Pritzker School of Medicine
    2009Resident Research Grant, College of American Pathologists
    2010Robert W. Wissler Fellowship Award, Department of Pathology
    2011Leukemia and Lymphoma Society Fellow Award
    2013Leukemia and Lymphoma Society, Illinois Chapter Researcher of the Year
    2013Evans Travel Award, FASEB Hematologic Malignancies Science Research Conference
    2013Cancer Research Foundation Young Investigator Award
    2014“V” Foundation in Cancer Research Scholar Award
    2015Nachman Fellow, Dept. of Pediatrics Hematology-Oncology
    2017American Society of Hematology Junior Faculty Scholar Award
    2019American Cancer Society Research Scholar Award
    2020Faculty Award for Excellence in Graduate Teaching and Mentoring

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Jotte MRM, McNerney ME. The significance of CUX1 and chromosome 7 in myeloid malignancies. Curr Opin Hematol. 2022 03 01; 29(2):92-102. PMID: 35084368.
      View in: PubMed
    2. Baeten JT, Liu W, Preddy IC, Zhou N, McNerney ME. CRISPR screening in human hematopoietic stem and progenitor cells reveals an enrichment for tumor suppressor genes within chromosome 7 commonly deleted regions. Leukemia. 2022 05; 36(5):1421-1425. PMID: 35034954.
      View in: PubMed
    3. Krishnan M, Senagolage MD, Baeten JT, Wolfgeher DJ, Khan S, Kron SJ, McNerney ME. Genomic studies controvert the existence of the CUX1 p75 isoform. Sci Rep. 2022 01 07; 12(1):151. PMID: 34997000.
      View in: PubMed
    4. Ludwig LM, Hawley KM, Banks DB, Thomas-Toth AT, Blazar BR, McNerney ME, Leverson JD, LaBelle JL. Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells. Cell Death Dis. 2021 10 27; 12(11):1005. PMID: 34707089.
      View in: PubMed
    5. Imgruet MK, Lutze J, An N, Hu B, Khan S, Kurkewich J, Martinez TC, Wolfgeher D, Gurbuxani SK, Kron SJ, McNerney ME. Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms. Blood. 2021 09 02; 138(9):790-805. PMID: 34473231.
      View in: PubMed
    6. Imgruet MK, Lutze J, An NN, Hu B, Khan S, Kurkewich J, Martinez TC, Wolfgeher DJ, Gurbuxani S, Kron SJ, McNerney ME. Loss of a 7q gene, CUX1, disrupts epigenetic-driven DNA repair and drives therapy-related myeloid neoplasms. Blood. 2021 May 26. PMID: 34041524.
      View in: PubMed
    7. Stoddart A, Wang J, Fernald AA, Davis EM, Johnson CR, Hu C, Cheng JX, McNerney ME, Le Beau MM. Cytotoxic Therapy-Induced Effects on Both Hematopoietic and Marrow Stromal Cells Promotes Therapy-Related Myeloid Neoplasms. Blood Cancer Discov. 2020 07; 1(1):32-47. PMID: 32924016.
      View in: PubMed
    8. Cahill KE, Karimi YH, Karrison TG, Jain N, Green M, Weiner H, Fulton N, Kadri S, Godley LA, Artz AS, Liu H, Thirman MJ, Le Beau MM, McNerney ME, Segal J, Larson RA, Stock W, Odenike O. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606. PMID: 32074275.
      View in: PubMed
    9. McNerney ME, Le Beau MM. The Harmful Consequences of Increased Fitness in Hematopoietic Stem Cells. Cell Stem Cell. 2018 11 01; 23(5):634-635. PMID: 30388419.
      View in: PubMed
    10. Kang W, Kadri S, Puranik R, Wurst MN, Patil SA, Mujacic I, Benhamed S, Niu N, Zhen CJ, Ameti B, Long BC, Galbo F, Montes D, Iracheta C, Gamboa VL, Lopez D, Yourshaw M, Lawrence CA, Aisner DL, Fitzpatrick C, McNerney ME, Wang YL, Andrade J, Volchenboum SL, Furtado LV, Ritterhouse LL, Segal JP. System for Informatics in the Molecular Pathology Laboratory: An Open-Source End-to-End Solution for Next-Generation Sequencing Clinical Data Management. J Mol Diagn. 2018 07; 20(4):522-532. PMID: 29698836.
      View in: PubMed
    11. An N, Khan S, Imgruet MK, Gurbuxani SK, Konecki SN, Burgess MR, McNerney ME. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood. 2018 06 14; 131(24):2682-2697. PMID: 29592892.
      View in: PubMed
    12. Gyawali B, Parsad S, Feinberg BA, Nabhan C. Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance. JCO Precis Oncol. 2017 Nov; 1:1-5. PMID: 25043302.
      View in: PubMed
    13. Gyawali B, Parsad S, Feinberg BA, Nabhan C. Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance. JCO Precis Oncol. 2017 Nov; 1:1-5. PMID: 11086108.
      View in: PubMed
    14. Gyawali B, Parsad S, Feinberg BA, Nabhan C. Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance. JCO Precis Oncol. 2017 Nov; 1:1-5. PMID: 20383307.
      View in: PubMed
    15. McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017 08 24; 17(9):513-527. PMID: 28835720.
      View in: PubMed
    16. Arthur RK, An N, Khan S, McNerney ME. The haploinsufficient tumor suppressor, CUX1, acts as an analog transcriptional regulator that controls target genes through distal enhancers that loop to target promoters. Nucleic Acids Res. 2017 Jun 20; 45(11):6350-6361. PMID: 28369554.
      View in: PubMed
    17. Stricker TP, Brown CD, Bandlamudi C, McNerney M, Kittler R, Montoya V, Peterson A, Grossman R, White KP. Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression. PLoS Genet. 2017 03; 13(3):e1006589. PMID: 28263985.
      View in: PubMed
    18. Kadri S, Long BC, Mujacic I, Zhen CJ, Wurst MN, Sharma S, McDonald N, Niu N, Benhamed S, Tuteja JH, Seiwert TY, White KP, McNerney ME, Fitzpatrick C, Wang YL, Furtado LV, Segal JP. Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays. J Mol Diagn. 2017 01; 19(1):43-56. PMID: 27836695.
      View in: PubMed
    19. Stoddart A, Qian Z, Fernald AA, Bergerson RJ, Wang J, Karrison T, Anastasi J, Bartom ET, Sarver AL, McNerney ME, Largaespada DA, Le Beau MM. Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms. Haematologica. 2016 06; 101(6):e232-6. PMID: 26944478.
      View in: PubMed
    20. Zhao Z, Chen CC, Rillahan CD, Shen R, Kitzing T, McNerney ME, Diaz-Flores E, Zuber J, Shannon K, Le Beau MM, Spector MS, Kogan SC, Lowe SW. Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nat Genet. 2015 May; 47(5):539-43. PMID: 25822087.
      View in: PubMed
    21. Wang X, Fu AQ, McNerney ME, White KP. Widespread genetic epistasis among cancer genes. Nat Commun. 2014 Nov 19; 5:4828. PMID: 25407795.
      View in: PubMed
    22. McNerney ME, Brown CD, Peterson AL, Banerjee M, Larson RA, Anastasi J, Le Beau MM, White KP. The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q). Br J Haematol. 2014 Aug; 166(4):550-6. PMID: 24931631.
      View in: PubMed
    23. Heath AP, Greenway M, Powell R, Spring J, Suarez R, Hanley D, Bandlamudi C, McNerney ME, White KP, Grossman RL. Bionimbus: a cloud for managing, analyzing and sharing large genomics datasets. J Am Med Inform Assoc. 2014 Nov-Dec; 21(6):969-75. PMID: 24464852.
      View in: PubMed
    24. Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov. 2013 Sep; 3(9):993-1001. PMID: 23733505.
      View in: PubMed
    25. Brägelmann J, Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, Vokes EE, White KP, Cohen EE, Seiwert TY. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncol. 2013 Jun; 49(6):525-33. PMID: 23490885.
      View in: PubMed
    26. McNerney ME, Brown CD, Wang X, Bartom ET, Karmakar S, Bandlamudi C, Yu S, Ko J, Sandall BP, Stricker T, Anastasi J, Grossman RL, Cunningham JM, Le Beau MM, White KP. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood. 2013 Feb 07; 121(6):975-83. PMID: 23212519.
      View in: PubMed
    27. Stoddart A, McNerney ME, Bartom E, Bergerson R, Young DJ, Qian Z, Wang J, Fernald AA, Davis EM, Larson RA, White KP, Le Beau MM. Genetic pathways leading to therapy-related myeloid neoplasms. Mediterr J Hematol Infect Dis. 2011; 3(1):e2011019. PMID: 21713073.
      View in: PubMed
    28. Godley LA, Cunningham J, Dolan ME, Huang RS, Gurbuxani S, McNerney ME, Larson RA, Leong H, Lussier Y, Onel K, Odenike O, Stock W, White KP, Le Beau MM. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24. PMID: 21421111.
      View in: PubMed
    29. Alegre ML, McNerney ME. Natural killer cell subsets in allograft rejection and tolerance. Curr Opin Organ Transplant. 2007 Feb; 12(1):10-16. PMID: 27792083.
      View in: PubMed
    30. McNerney ME, Lee KM, Zhou P, Molinero L, Mashayekhi M, Guzior D, Sattar H, Kuppireddi S, Wang CR, Kumar V, Alegre ML. Role of natural killer cell subsets in cardiac allograft rejection. Am J Transplant. 2006 Mar; 6(3):505-13. PMID: 16468959.
      View in: PubMed
    31. McNerney ME, Kumar V. The CD2 family of natural killer cell receptors. Curr Top Microbiol Immunol. 2006; 298:91-120. PMID: 16323413.
      View in: PubMed
    32. Lee KM, Forman JP, McNerney ME, Stepp S, Kuppireddi S, Guzior D, Latchman YE, Sayegh MH, Yagita H, Park CK, Oh SB, Wülfing C, Schatzle J, Mathew PA, Sharpe AH, Kumar V. Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions. Blood. 2006 Apr 15; 107(8):3181-8. PMID: 15905190.
      View in: PubMed
    33. McNerney ME, Guzior D, Kumar V. 2B4 (CD244)-CD48 interactions provide a novel MHC class I-independent system for NK-cell self-tolerance in mice. Blood. 2005 Aug 15; 106(4):1337-40. PMID: 15870174.
      View in: PubMed
    34. Kumar V, McNerney ME. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat Rev Immunol. 2005 May; 5(5):363-74. PMID: 15841099.
      View in: PubMed
    35. McNerney ME, Lee KM, Kumar V. 2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells. Mol Immunol. 2005 Feb; 42(4):489-94. PMID: 15607804.
      View in: PubMed
    36. Vaidya SV, Stepp SE, McNerney ME, Lee JK, Bennett M, Lee KM, Stewart CL, Kumar V, Mathew PA. Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. J Immunol. 2005 Jan 15; 174(2):800-7. PMID: 15634901.
      View in: PubMed
    37. Lee KM, McNerney ME, Stepp SE, Mathew PA, Schatzle JD, Bennett M, Kumar V. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J Exp Med. 2004 May 03; 199(9):1245-54. PMID: 15123744.
      View in: PubMed
    Mcnerney's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (203) concept(s)
    _
    Co-Authors Expand Description
    See all (35) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department
    Physical Neighbors Expand Description
    _